Make Kitco Your Homepage

Pfizer lifts sales forecast for COVID-19 vaccine to $26 billion

Kitco News

(Reuters) -Pfizer Inc on Tuesday forecast $26 billion in sales of the COVID-19 vaccine this year, an increase of more than 70% from its last projection and a reflection of the growing global vaccination drive.

The vaccine, which it co-developed with Germany's BioNTech SE, generated $3.5 billion in revenue in the first quarter, beating the consensus estimate of $3.28 billion, according to six analysts polled by Refinitiv.

"Based on what we've seen, we believe that a durable demand for our COVID-19 vaccine – similar to that of the flu vaccines – is a likely outcome,” Chief Executive Officer Albert Bourla said in his prepared remarks ahead of the conference call.

Cost and gross profit from the vaccine are split 50-50 between Pfizer and BioNTech. The raised goal assumes 1.6 billion vaccine doses will be delivered in the year.

The U.S. drugmaker had previously forecast sales of $15 billion. It now expect to manufacture at least 3 billion doses of the vaccine next year.

The two-dose vaccine has shown an efficacy rate of more than 90% in late-stage trials, on par with Moderna Inc's vaccine but higher than the rates seen from AstraZeneca plc and Johnson & Johnson.

Moderna has forecast $18.4 billion in 2021 sales of its COVID-19 vaccine.

Pfizer has said it expects to profit from the vaccine, while some drugmakers including Johnson & Johnson have said their vaccine will be available on a not-for-profit basis until the end of the pandemic.

Shares the company was up 1.5% in premarket trading.

Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur

Disclaimer: The views expressed in this article are those of the author and may not reflect those of Kitco Metals Inc. The author has made every effort to ensure accuracy of information provided; however, neither Kitco Metals Inc. nor the author can guarantee such accuracy. This article is strictly for informational purposes only. It is not a solicitation to make any exchange in commodities, securities or other financial instruments. Kitco Metals Inc. and the author of this article do not accept culpability for losses and/ or damages arising from the use of this publication.